Onconova Therapeutics Inc (NASDAQ:ONTX) major shareholder Tyndall Capital Partners L. P sold 10,927 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $2.83, for a total transaction of $30,923.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Shares of ONTX stock opened at $2.57 on Friday. The company has a 50-day moving average price of $3.20. Onconova Therapeutics Inc has a twelve month low of $1.69 and a twelve month high of $11.17. The firm has a market cap of $15.42 million, a P/E ratio of -0.52 and a beta of 2.69.
Onconova Therapeutics (NASDAQ:ONTX) last announced its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.18). Onconova Therapeutics had a negative net margin of 3,153.42% and a negative return on equity of 310.58%. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.08 million. As a group, equities analysts expect that Onconova Therapeutics Inc will post -3.39 EPS for the current fiscal year.
Several brokerages recently weighed in on ONTX. HC Wainwright set a $25.00 target price on shares of Onconova Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 14th. Maxim Group reissued a “buy” rating and issued a $16.00 target price on shares of Onconova Therapeutics in a research note on Tuesday, May 14th. Zacks Investment Research raised shares of Hudson Technologies from a “sell” rating to a “hold” rating in a research note on Wednesday, May 29th. Finally, ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS.
Recommended Story: What is meant by holder of record?
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.